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Potassium channelhERG (human Ether-à-go-go Related Gene) is responsible for ion channels mediating rapid delayed rectiﬁer
potassium current, IKr, which is key to cardiac action potential repolarization. Gain-of-function hERG
mutations give rise to the SQT1 variant of the Short QT Syndrome (SQTS). Reggae mutant zebraﬁsh, with a S4
zERGmutation (Leucine499Proline; L499P), display arrhythmic features analogous to those seen in the SQTS.
The affected S4 domain ERG residue is highly conserved. This study was executed to determine how the
homologous hERG mutation (L532P) inﬂuences channel function at 37 °C. Whole-cell measurements of
current (IhERG) were made from HEK 293 cells expressing WT or L532P hERG. The half maximal activation
voltage (V0.5) of L532P IhERG was positively shifted by ~+36 mV compared to WT IhERG; however at negative
voltages a pronounced L532P IhERG was observed. Both activation and deactivation time-courses were
accelerated for L532P IhERG. The inactivation V0.5 for L532P IhERG was shifted by ~+32 mV. Under action
potential (AP) voltage-clamp, L532P IhERG exhibited a dome-shaped current peaking at ~+16 mV, compared
to ~−31 mV for WT-IhERG. The L532P mutation produced an ~5-fold increase in the IC50 for dronedarone
inhibition of IhERG. Homology modeling indicated that the L532 residue within the S4 helix lies closely
apposed to the S5 region of an adjacent hERG subunit. Alterations to the S4 domain structure and, potentially,
to interactions between adjacent hERG subunits are likely to account for the functional effects of this
mutation.+44 117 331 2288.
ox).
-NC-ND license.© 2011 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The cardiac rapid delayed rectiﬁer potassium channel passes ionic
current (IKr) thatplays an important role in cardiac actionpotential (AP)
repolarization [1,2]. The pore-forming subunit of IKr channels is encoded
by human Ether-à-go-go-Related Gene (hERG; alternative nomenclatures
KCNH2 or Kv11.1) [3,4]. Loss-of-function hERG mutations are respon-
sible for the LQT2 variant of congenital long QT syndrome (LQTS), while
unique structural features of the hERG channel render it highly
susceptible to pharmacological blockade and make it an important
target for antiarrhythmic drugs and drugs associated with the acquired
form of the LQTS [2,5–7].
Within the last decade the hERG channel has also been implicated
in the genetic ‘short QT syndrome’ (SQTS), a condition characterized
by abbreviated QT intervals, poor rate adaptation of the QT interval
and an increased susceptibility to both atrial and ventricular
arrhythmias and to sudden death [8,9]. The ﬁrst variant of the SQTS
to be genotyped (SQT1) was found to be caused by base substitutions
leading to a single amino-acid change (Asn588Lys; ‘N588K’) in the
S5-Pore linker of the hERG channel [10,11]. Detailed electrophysio-
logical analysis of N588K-hERG showed the dominant effect of themutation to be a marked right-ward shift (by ~+60 to +90 mV) in
the voltage-dependence of inactivation of hERG current (IhERG),
leading to substantially increased current during the repolarizing
phases of both ventricular and atrial APs [10,12–14]. Due to its
markedly altered inactivation properties, the N588K hERG mutant
also exhibits markedly reduced sensitivity to Class III antiarrhythmic
IKr inhibitors (sotalol, E-4031), withmuch less of an attenuation of the
effect of Class Ia drugs (quinidine, disopyramide) [10,15,16]. A second
SQT1 hERG channel gain-of-function pore mutation (Thr618Ile;
‘T618I’ located in the channel pore-helix), which also exhibits
modiﬁed inactivation kinetics, has recently been reported [32].
There is no genetically accurate mammalian model of SQT1;
consequently, efforts to understand the basis of arrhythmogenicity
in this form of the SQTS have relied either on computer modeling (e.g.
[17–20]) or upon the application of K+ channel openers to tissue
preparations [21–24].
The only existing vertebrate genetic model of a hERG-linked
SQTS-like arrhythmogenic syndrome is the zebraﬁsh Reggae mutant
[25]. Reggae mutant zebraﬁsh embryos exhibit action potential
abbreviation, cardiac ﬁbrillation and intermittent cardiac arrest,
while adult ﬁsh exhibit shorted QTc intervals [25]. Positional cloning
has identiﬁed the mutation responsible as residing in exon 8 of the
zebraﬁsh ERG channel (zERG) [25]. A leucine to proline substitution
(L499P) was found in the S4 (voltage-sensor) region of zERG. This
region is highly conserved across species (Fig. 1A and see [25]) with
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Fig. 1. (A) Amino acid sequence alignment for region encompassing zebraﬁsh (zERG) L499 with human (hERG), horse (eERG), dog (dERG), rat (rERG) and mouse (mERG). Domains
S4, S5 and the S4–S5 linker are indicated below the sequences. The L at position 532 of hERG is highly conserved across species and is highlighted in gray. (B) Example current traces
forWT (upper panel of Bi) and mutant L532P IhERG (upper panel of Bii) with corresponding voltage protocol used shown in the lower panels. Note that the current scales in Bi and Bii
differ. Inset to Bii shows higher gain representation of L532P tail current.
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analysis of L499P zERG and L532P hERG in Xenopus oocytes has shown
gain-of-function kinetic effects of the mutation, with alterations to
activation and inactivation voltage-dependence over physiologically
relevant membrane potentials [25]. Due to the fact that the L532
residue is located in a different segment of the channel to those in
which the N588 and T618 residues reside, detailed information on the
nature of the distinct kinetic changes produced by the L532P hERG
mutation and its net effect on repolarizing current proﬁle would
provide valuable comparative information to that presently available
for these human short QT hERG mutations. The kinetics of IhERG have
been shown to exhibit a complex temperature dependence, making it
difﬁcult to extrapolate directly results obtained at ambient temper-
ature to human body temperature [26]; properties of recombinant
hERG channels also appear to be closest to those of native IKr when
channels are expressed in a mammalian cell line and studied at
human body temperature [2,27]. Consequently, the present study was
undertaken to determine the effects of the L532P mutation on IhERG
recorded from mammalian cells at 37 °C. Our results: (i) constitute
quantitative information on the effects of the L532P mutation on both
voltage and time-dependent kinetics of IhERG; (ii) demonstrate the
ability of this mutation to alter the hERG channel's sensitivity to
pharmacological inhibition and (iii) indicate the structural context for
the affected amino-acid residue of the channel.
2. Material and methods
2.1. Mutagenesis
The L532P hERG mutation was generated using the QuickChange®
site-directed mutagenesis kit (Stratagene, La Jolla, CA). In brief, a pair of
complementary oligonucleotide primers containing the mutation
(forward primer sequence 5′CTGCTGCGGCCGGTGCGCGTG3′ and re-
verse primer sequence 5′CACGCGCACCGGCCGCAGCAG3′, synthesized
by Sigma-Genosys, Haverhill, UK) was used in a PCR reaction (95 °C for1 min, 60 °C for 1 min, 68 °C for 16 min for 18 cycles) by using hERG in a
modiﬁed pcDNA3.0 vector as a DNA template. A DpnI digest of the PCR
mix was then performed for 1 h at 37 °C. Competent DH5α Escherichia
coli (Invitrogen, Paisley, UK) were transformed using standard pro-
cedures. The mutation was conﬁrmed by sequencing of the entire open
reading frame (Euroﬁns MWG Operon, Ebersberg, Germany).
2.2. Cell culture and transfection
HEK 293 cells (European Collection of Cell Cultures, Porton Down,
UK) weremaintained at 37 °C, 5% CO2 in Dulbecco's minimum essential
medium with Glutamax-1 (DMEM; Gibco, Paisley, UK). This was
supplemented with 10% fetal bovine serum, 50 μg ml−1 gentamycin
(Gibco, Paisley, UK). Cells were transiently transfected with cDNA
plasmids encoding WT and mutant hERG using Lipofectamine LTX
(Invitrogen, Paisley, UK) according to the manufacturer's instructions.
Expression plasmid encoding CD8was also added (in pIRES, donated by
Dr I Baró, University of Nantes, France) to be used as a successfulmarker
of transfection. Recordings were performed 12–72 h after transfection.
Successfully transfected cells (positive to CD8) were identiﬁed using
Dynabeads® (Invitrogen, Paisley, UK).
2.3. Solutions for electrophysiological recordings
Once in the recording chamber, cells were superfused with normal
Tyrode's containing (in mM): 140 NaCl, 4 KCl, 2.5 CaCl2, 1 MgCl2, 10
Glucose, and 5HEPES (titrated to pHof 7.45withNaOH). Patch-pipettes
were ﬁre-polished to 2.5–4 MΩ. The pipette dialysis solution for IhERG
measurement contained (in mM): 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP,
and 10 HEPES (titrated to pH of 7.2 with KOH). Dronedarone powder
(Sequoia Research Products, Pangbourne, UK) was dissolved in ethanol
to produce an initial stock solution of 50 mM,whichwas serially diluted
to produce stock solutions ranging from 50 mM to 3 μM; these were
diluted 1:1000 fold with Tyrode's solution to achieve the ﬁnal super-
fusate drug concentrations stated in the ‘Results’.
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Whole cell conventional and human action potential (AP) voltage
clamp recordings of hERG current (IhERG) were made at 37±1 °C as
previously reported [33]. Data digitization rates were 10–25 kHz
during all protocols and an appropriate bandwidth of 2–10 kHz was
set on the ampliﬁer. Note that L532P IhERG exhibited considerable cell-
to-cell heterogeneity in amplitude, presumably due to variable
transfection efﬁciency; consequently in a number of ﬁgures WT and
L532 IhERG are displayed with different current scales (this is
highlighted in the relevant ﬁgure legends). Statistical comparisons
were made using a Student's t-test or two way analysis of variance
(ANOVA) followed by Tukey post hoc test, as appropriate. P values of
less than 0.05 were taken as being statistically signiﬁcant.
2.5. Concentration–response data correction for IhERG run-down
As previously reported [29], in this study dronedarone exhibited a
progressive development of IhERG blockade, reaching a stable level of
block by 10 min of drug exposure. During this period, there was some
overlying run-down of IhERG. Therefore, control experiments were
performed. For these, WT and L532P IhERG were monitored during a
2–4 min stabilization period by repeated use of the standard voltage
‘step’ protocol, followed by a 10 min recording period in normal
Tyrode's solution. The mean level of run-down of WT IhERG tails over
10 min was 13.4±1.6% of the peak tail magnitude (n=6 cells)
while for L532P IhERG tails this was 15.7±2.5% (n=6 cells). To correct
concentration–response data for IhERG run-down, we subtracted 13.4%
of WT or 15.7% of L532P current magnitude from the last tail current in
the control periods and used the resulting value to calculate fractional
block following (10 min) exposure to dronedarone.
2.6. Homology modeling
A full open-state homology model of the hERG membrane domain
was constructed using the crystal structure of a Kv1.2/Kv2.1 paddle
chimera (PDB ID: 2R9R) determined by Long et al [35]. The template
was retrieved from the RCSB Protein Data Bank as a monomer.
ClustalW2, TMPred and UNIPROT were used to perform the sequence
alignment, which was reﬁned manually with the help of literature
regarding hERG and other Kv channels. Full details of the model will
be described elsewhere; however the homology used to align the S4
sequence of hERG into the paddle chimera structure is shown in Fig. 7.
Amino acid substitutions, including generation of the L532Pmutation,
were made using the Biopolymer function within InsightII (Accelrys),
and the Protein Data Bank was used to search for suitable linker
constructs including the extracellular turret region. The symmetry
operator within the PDB ﬁle 2R9R was used to construct a
homotetramer and hERG monomers were superimposed onto this
to generate a tetrameric homology model of hERG. The ﬁnal open
channel hERG homology model and the L532P mutant were energy
minimized using Discover 2.9.8 (Accelrys). The stereochemical quality
of the structures was veriﬁed using PROCHECK [49].
3. Results
3.1. Effects of the L532P mutation on IhERG proﬁles during a standard
voltage ‘step’ protocol
Fig. 1B shows proﬁles of WT and L532P IhERG elicited by a protocol
composed of depolarizing voltage commands from −80 to +20 mV
and a repolarizing step to−40 mV.WT IhERG (Fig. 1Bi) exhibited well-
established characteristics: current development during the applied
depolarization, with a larger IhERG ‘tail’ elicited during a repolarizing
step to −40 mV (end pulse current was 0.48±0.04 fold that of tail
current amplitude; n=14 cells). By contrast L532P IhERG increasedrapidly on step-depolarization, with current during the +20 mV step
that was much larger than the IhERG tail on repolarization to−40 mV
(Fig. 1Bii; end pulse current amplitude was 1.45±0.09 fold that of tail
current amplitude; n=43 cells). Tail current decline was much faster
for L532P than for WT IhERG (compare Fig. 1Bii (and inset) with
Fig. 1Bi).
The voltage-dependence ofWT and L532P IhERGwas compared using
2 s depolarizing voltage steps from−80 mV topotentials between−40
and +60mV. Representative traces are shown in Fig. 2A and B for WT
and L532P hERG respectively. WT IhERG increased progressively with
depolarization up to ~0 mV, declining atmore positive potentials, giving
rise to marked negative slope in the current–voltage (I–V) relation
(Fig. 2A, C). Proportionately greater L532P thanWT IhERGwas elicited by
depolarization to −40 and −30 mV, but then smaller increases in
current were seen with progressive depolarization up to 0–+10mV
(Fig. 2B, C). Rectiﬁcation of L532P IhERGwas evident at positive voltages.
The normalized mean I–V data shown in Fig. 2C show the more gradual
increase in L532P than WT IhERG up to ~0–+10 mV and positively
shifted rectiﬁcation of the end pulse I–V relationship. Normalized I–V
relations for IhERG tail currentswere used to compare voltage dependent
activation of the two channels, with Boltzmann ﬁtting used to derive
half-maximal activation voltage (V0.5) and slope (k) values. At−40 mV
therewas signiﬁcantly greater L532P IhERG activation than forWT-hERG;
however at potentials between−20 mV and ~+30mV, activation was
signiﬁcantly less extensive for mutant than WT channels, with a
shallower slope of the activation relationship (Fig. 2D). Derived V0.5 and
k values for WT IhERG were −16.6±2.3 mV and 6.8±0.3 mV (n=7),
while for L532P these were +19.2±2.8 mV and 12.4±0.9 mV (n=9,
Pb0.001 for both V0.5 and k versus WT). Thus, L532P hERG showed
greater activation thanWT IhERG but an ~+36mV shift in activation V0.5
compared to the WT channel.
3.2. Effects of the L532P mutation on the fully activated I–V relation and
on deactivation and activation time-courses
The protocol used to elicit the fully activated I–V relation and
quantify deactivation (identical to that used previously in [13,31]) is
shown in Fig. 3Aii, with representative current traces for WT IhERG in
Fig. 3Ai and for L532P IhERG in Fig. 3B. For both channels, the peak current
on the repolarizing steps to different voltages was normalized to the
maximal observed peak current during the protocol and plotted against
voltage [13,31], see Fig. 3C. ForWT IhERG, the fully activated I–V relation
was maximal for the repolarizing step to ~−30 mV, whereas for L532P
IhERG this was positively shifted. The WT hERG fully activated I–V
relation reversed at −84.3±0.9 mV (n=6), whereas the comparable
value for L532Pwas−80.3±0.8 mV (n=9; Pb0.005). The deactivating
component of Itails at each repolarization step was ﬁtted with a bi-
exponential function to derive fast and slow(τf and τs) time constants of
deactivation (plotted in Fig. 3D and E). Both τf and τs values were
signiﬁcantly smaller for L532P IhERG than for WT IhERG at repolarization
potentials of -60 mV and more positive. There were also signiﬁcant
differences betweenWT and L532P hERG atmostmembrane potentials
examined for the fraction of deactivation described by τf (Fig. 3F). An
additional observation was that, while bi-exponential ﬁts to deactivat-
ing WT IhERG tails yielded little residual unﬁtted current at negative
voltages (for example, residual unﬁtted components of only 3.4±1.0%
and 3.2±0.8% of peak tail current were obtained respectively at −60
and−70 mV), for L532P substantial residual current remained. Thus at
−60 mV residual unﬁtted current for L532P IhERG was 23.4±4.9% of
peak tail current (Pb0.01 compared to WT), although at −70 mV the
greater residual IhERG for L532P-hERG (12.4±4.6% of peak tail current)
did not attain statistically signiﬁcant difference from WT hERG
(PN0.05). The presence of residual current is consistent with greater
current activation at some negative voltages for L532P hERG (see also
Fig. 2D), though perhaps not with complete destabilization of closed
channel state(s). An envelope of tails protocol (inset of Fig. 3G; see also
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between the two channels at +20mV. Mono-exponential ﬁtting of
mean normalized tail currents elicited by the protocol (Fig. 3G) yielded
for WT IhERG a τact of 67.9±6.1 ms (n=9) and of 32.6±2.2 ms for
L532P IhERG (n=6, Pb0.001). Additional analysis of pulse currents
elicited by the I–V protocol shown in Fig. 2A, B between−40 and 0 mV
yielded signiﬁcantly reduced values for time to half-maximal current
(thalf) at each potential for L532P (at -30 mV thalf was 30±10ms for
L532P IhERG compared to 490±30ms for WT IhERG, Pb0.001; while at
0 mV the respective values were 10±2 ms and 130±40ms, Pb0.01).
Collectively, these results indicate that, over a range of potentials, L532P
IhERG both activated and deactivated faster than did WT IhERG
3.3. Effects of the L532P mutation on voltage and time dependence of
inactivation
The voltage-dependence of WT IhERG inactivation (availability) was
assessed using the protocol shown in Fig. 4A (and lower trace in 4 C): an
initial step to +40 mV activated and then inactivated IhERG; a ‘ladder’ of
brief (2 ms) repolarizing steps to a range of potentials (to relieve
inactivation to varying extents)was followed bya third step to+40 mV.
The magnitude of peak current elicited by the third step reﬂected the
extent of availability induced by the second step. Representative WT
IhERG records are shown in Fig. 4C. In order to correct for possible
deactivation during this protocol, as in previous work from our
laboratory [13], a method described by Zou et al [52] was used: peak
current amplitudes during the third pulse were obtained by singleexponential ﬁtting of the currents and extrapolation to the start of the
third step. Peak currents during the third step were then normalized to
maximal current and mean data were plotted as shown in Fig. 4E.
Boltzmann ﬁtting this relation yielded an inactivation V0.5 value of
−70.3±1.7 mV (k=19.6±0.5 mV; n=9). As rectiﬁcation of the I–V
relation for L532P IhERG in Fig. 2C was positively shifted, in order to
ensure adequate inactivation during the availability protocol, the
protocol was modiﬁed so that the ﬁrst and third step potential was set
to +80 mV (Fig. 4B, lower trace in 4D; see [13]). Representative traces
are shown in Fig. 4D with mean normalized data shown in Fig. 4E.
Boltzmann-ﬁtting of this plot gave an inactivation V0.5 for L532P IhERG of
−38.7±3.7 mV (k=28.7±2.8 mV, n=6, Pb0.0001 for V0.5 and
Pb0.005 for k value compared with WT). Calculation of the steady-
state activation-inactivation parameter product (“window current”)
across awide range of voltages (−80 mV to+60 mV) forWTandL532P
IhERG indicated slightly greater window current for L532P thanWT IhERG
at potentials negative to approximately -50 mV and much greater
windowcurrent for L532PhERGpositive to approximately−5 mV(data
not shown). The currents elicited following the repolarizing step to
-140 mV were also used to quantify the time-course of development of
inactivation (from a single-exponential ﬁt) for the two channels; the
τ-values obtained forWTand L532P IhERGwere 1.34±0.13 msand1.0±
0.06 ms respectively (PN0.05). The rate of recovery from inactivation
was assessed using the protocol shown in the inset of Fig. 4F and see
[14,34]. Normalized peak outward transient currents were plotted
against the duration of the repolarization step and ﬁtted with a mono-
exponential function, giving τ values of 1.92±0.07 ms for WT (n=10)
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that the greatly accelerated deactivation for L532P meant that after the
ﬁrst 2–3 current transients, the amplitude of successive transients
declined. To highlight this, the plot in Fig. 4F also shows consecutive
points for L532P joined by dotted straight lines. Collectively, the data
shown in Fig. 4 indicate that thevoltage-dependenceof IhERG inactivation
was positively shifted (a V0.5 shift of +32 mV), with a modest
acceleration in recovery of inactivation.Table 1 summarizes the biophysical parameters obtained for WT
and L532P IhERG
3.4. L532P IhERG proﬁle during ventricular AP clamp
An example trace of WT IhERG during the course of an imposed
ventricular AP waveform is shown in Fig. 5Ai, while Fig. 5Aii shows a
comparable trace for L532P IhERG (black trace, with the WT current
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increased progressively through the AP plateau phase, before
declining during terminal AP repolarization (Fig. 5Ai and see
[13,31,33]). By contrast, L532P IhERG increased much earlier during
the AP command, peaking earlier during the AP plateau phase, with a
‘domed’ or ‘inverted U’ shaped proﬁle andmore rapid decline than the
WT current during the terminal AP phase (Fig. 5Aii). Fig. 5B shows the
mean normalized instantaneous I–V relation for WT IhERG during AP
repolarization, with maximal current relatively late in repolarization
(at −30.7±2.1 mV; n=7 cells). Fig. 5C shows the mean instanta-
neous I–V relation for L532P IhERG, with current rising to a maximal
value at +15.7±2.4 mV (n=8; Pb0.0001 versus WT) early in
repolarization, then declining linearly with repolarization voltage
3.5. Modulation by L532P of pharmacological inhibition of IhERG by
dronedarone
Further experimentswere performed inwhich effectswere assessed
of the L532P mutation on pharmacological inhibition of IhERG. For theseexperiments, the Class III antiarrhythmic agent dronedarone (Droned)
was chosen; this drug is a non-iodinated analog of amiodarone that
exhibits hERG inhibition involving interaction with both activated and
inactivated channels [29]. The voltage protocol used was composed of a
2 s voltage command to +20 mV, followed by repolarization to
−40 mV to observe IhERG tails. It also incorporated a brief (50 ms)
pre-pulse from−80 to−40 mV prior to the test command, in order to
quantify the instantaneous current at −40 mV. Comparison between
this instantaneous current and the peak outward IhERG tail amplitude on
repolarization to−40 mV facilitated accuratemeasurement ofWT IhERG
tail amplitude (cf [30,53]). For consistency the same protocol was
applied in experiments on both WT and L532P IhERG. Fig. 6A shows
effects of 300 nM dronedarone on WT IhERG while Fig. 6B shows
comparable data for L532P IhERG; current inhibition by the drug was
more extensive for theWT than themutant channel. Fig. 6C showsmean
(run-down corrected) data for a range of drug concentrations, in which
fractional block at each concentration plotted against the Log [Drone-
darone] concentration. The datawere ﬁttedwith a Hill equation and the
derived IC50 and Hill co-efﬁcient were 42.6±3.4 nM and 0.9±0.1 for
Table 1
Comparison of biophysical parameters for WT and L532P hERG.
Property WT L532P
Vact 0.5(mV) −16.6±2.3 19.2±2.8
k (activation, mV) 6.8±0.3 12.4±0.9
(n=7 for both) (n=9 for both)
τact (ms) 67.9±6.1 32.6±2.2
(n=9) (n=6)
Erev (mV) −84.3±0.9 −80.3±0.8
(n=6) (n=9)
Vinact0.5(mV) −70.3±1.7 −38.7±3.7
k (inactivation,mV) 19.6±0.5 28.7±2.8
(n=9 for both) (n=6 for both)
τinact (ms) 1.34±0.13 1.0±0.06
(n=9) (n=6)
τrec (ms) 1.92±0.07 1.43±0.12
(n=10) (n=11)
Abbreviations: Vact 0.5, half-maximal activation voltage; τact, time constant of activation;
Erev, reversal potential; Vinact0.5, half-maximal inactivation voltage; k, slope factor for
activation or inactivation relationship; τinact, time constant of inactivation; τrec, time
constant of recovery from inactivation; n=number of experimental replicates. Data are
presented as mean±s.e. mean.
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L532Pmutation resulted in a 5.3-fold rightward shift in the IC50 for IhERG
block by dronedarone (Pb0.005 for WT and mutant IC50 values).
3.6. Homology modeling
In the absence of direct structural information from crystal
structures of (h)ERG channels, homology modeling offers a useful
way of investigating potential structural context(s) for changes to
hERG channel function. Therefore, we adopted homology modeling
based on a Kv1.2/2.1 template, in order to explore the structural
context of the L532P mutation. The L532 residue resides in the helical
S4 transmembrane segment, composed of ~20 amino acids as-80
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arrows indicate the direction of AP repolarization.indicated by homology with eukaryotic voltage-gated channels of
known structure (e.g. [45] and [50]). As shown in Fig. 1A, the amino
acid sequence in this region is highly conserved, with positively
charged residues (arginines or lysines) regularly separated by two
hydrophobic residues. The hydrophobic leucine at residue 532 is
located after the second arginine (R531) in the C-terminal half of S4
(Figs. 1A, 7A). The alignment of S4 (and adjacent sequence) between
hERG and the Kv1.2/2.1 ‘paddle chimera’ channel reported by Long et
al [35], is shown in Fig. 7A. Homology modeling based on the paddle
chimera (see Methods) places the L532 residue near the external face
of the S4 helix where it lies close to the S5 helix of an adjacent subunit,
at least in the open form of the channel model (Fig. 7B).
4. Discussion
4.1. Summary of principal ﬁndings
Although some characteristics of L532P IhERG have been recorded
at ambient temperature from channels expressed in Xenopus oocytes
[25], to our knowledge there are no prior reports of similar data for
mammalian cell hERG expression at 37 °C. Moreover, no information
has hitherto been published on the effects of the L532P hERG
mutation on time-dependent activation/inactivation kinetics of IhERG
or upon channel structure. Our data are in agreement with results
obtained previously from Xenopus oocytes [25], in indicating a low
activation threshold for L532P compared to WT IhERG, with an
accompanying shift in activation V0.5 of ~+36 mV here compared to
~+41 mV in Xenopus oocytes [25]. However, a marked (~+50 mV)
shift in voltage-dependent inactivation of L532P IhERG from Xenopus
oocytes was reported, whereas, under our experimental conditions
the inactivation-shift produced by the mutation was somewhat less
extensive (~+30 mV shift in V0.5). In addition to these effects of the
mutation on voltage-dependent kinetics of IhERG, we also observed
faster IhERG activation (and deactivation) and faster recovery from0.0
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amarkedly altered current proﬁle under AP voltage clamp (Fig. 5). We
also provide the ﬁrst demonstration that this S4 mutation, which is
located in a region distinct from the S6 and inner helices that comprise
the canonical drug binding site on hERG [2,36], has the potential to
modify potency of drug block of IhERG.
4.2. The L532P mutation in the context of S4 involvement in hERG
channel gating
The hERG channel is distinguished by its rapid inactivation gating
and comparatively slow activation gating. It is generally believed that
slow activation of hERG starts from outward translation of the positive
charged residues in S4 voltage sensor across the membrane ﬁeld upon
changes in membrane potential, which in turn causes opening of an
activation gate involving S6 domains [28,37,41]. The S4–S5 linker has
been suggested to couple directly S4 movement to the activation gate
in hERG [38,39]. Alanine scanning mutagenesis and homology
modeling have suggested a spiral pattern on the S4 domain of
residues mutations to which perturb activation, with inactivation-
perturbing mutation positions mapped to a distinct face of the S4
helix [38,45]. Positively charged residues K525, R528 and K538 in S4have been suggested to be those most important for activation of the
channel, with residues R528 and R531 as key candidates for binding to
residues in other transmembrane domains through salt bridges and
with residue R531 implicated in stabilizing the open state [42–44].
Alanine substitution at L532 produced little perturbation of activation
or inactivation [45], whereas substitution with tryptophan (a bulkier
hydrophobic residue) has been reported to accelerate deactivation
rate, but to have comparatively little effect on activation rate [44]. The
presence of proline residues in transmembrane helices of membrane
proteins is well known to perturb helical structure [46]. Given this and
the key role identiﬁed for residue R531 in activation gating, it is
perhaps unsurprising that proline substitution at the adjacent L532
residue signiﬁcantly alters IhERG activation characteristics as it can be
anticipated to alter S4 structure and inﬂuence of this domain on the
S4–S5 linker. It has also been proposed that depolarization-induced
motions in the S4 domain can change the orientation of 583–597 helix
in the S5-P linker region of the channel or push it toward the pore,
thereby facilitating IhERG inactivation. Uponmembrane repolarization,
a reversal of the above S4 movements would occur [47]. Perturbation
of the S4 helix by proline could inﬂuence such interactions and the
modest but statistically signiﬁcant shift in IhERG reversal potential with
the L532P-hERG is consistent with an allosteric effect of the mutation
AB
Fig. 7. Location of L532 in the context of the Kv1.2/2.1 chimera-based model of hERG. (A) Homology between hERG and the Kv1.2/2.1 chimera in and around the S4 sequence that
was used for construction of this part of the hERG model. Amino acid identities are red; similarities are blue. The schematic above the sequences refers to the location of structural
elements in the hERGmodel. (B) Close up of a hERG homologymodel based on the crystal structure of the Kv1.2/Kv2.1 paddle chimera, illustrating juxtaposition of the voltage sensor
domain of one subunit (cyan/blue) with the pore domain of an adjacent subunit (pink/mauve). The L532 residue (red) in the S4 helix is oriented toward the S5 helix of an adjacent
subunit.
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reversal potential is consistent with a decrease in K+ over Na+ ion
selectivity; equivalent to a PNa/PK ratio of ~1.6-fold that forWT hERG).
Our homology modeling raises an additional possibility for the
inﬂuence of the L532P mutation on channel gating and drug binding
to side chains that line the permeation pathway (e.g. residues on S6).
In the context of the model (Fig. 7B) residue L532 lies closely apposed
to the S5 domain (lying opposite residues W568 and Y569 of the S5
domain of an adjacent hERG subunit, with a minimal distance
between atoms of the apposing residues of ~3.5 Å). This raises the
possibility of S4–S5 interactions that would be anticipated to differ
between L532- and P532-containing channels; these might be
transmitted to the S6 helix through the intimate interactions between
S5 and S6 [51]. Given the comparative lack of effect of alanine
substitution at L532 on activation/inactivation [45], one might
speculate that, if present, these interactions become signiﬁcant
when a proline side chain is present in this residue. Further targeted
mutagenesis work would be required to explore this possibility in
greater depth.
4.3. Phenotype comparison with the N588K and T618I gain-of-function
mutations
Under conditions comparable to those used in the present study, a
previous investigation reported a marked (~+60 mV) voltage-shift in
N588K IhERG inactivation without any accompanying shift in activa-
tion [13]. The recently discovered T618I mutation has been reported
to shift inactivation by ~+50 mV, with an additional ~−5 mV shift in
activation. Thus, both of these human SQTS hERG mutations produce
greater inactivation-shifts to that seen for L532P in the present study.
There are no AP clamp data currently available for T618I hERG, but
direct comparison is possible between our AP clamp data for L532PIhERG and N588K IhERG studied under similar conditions [13,14]. When
elicited by a ventricular AP waveform similar to that used here, N588K
IhERG exhibited a similar dome-shaped current, with maximal current
during repolarization occurring N60 mV positive to that for WT IhERG
[14]. Simulation data indicate that the altered timing and magnitude
of repolarizing IKr in the setting of the SQT1 N588K mutation leads to
marked ventricular AP abbreviation [17–19]. The AP abbreviation
with N588K is also associated with ﬂattening of the AP duration–
restitution curve [18] and the overall effects of this mutation are likely
to facilitate susceptibility to re-entrant arrhythmia. Despite differ-
ences from N588K-hERG in the overall effects on IhERG kinetics of the
L532P mutation, it resulted in a remarkably similar dome-shaped
IhERG proﬁle under AP clamp to that seen for N588K-hERG, with an ~
+47 mV shift in maximal outward current during repolarization. This
is consistent with the previously advanced notion based on in silico
modeling that kinetic changes produced by the L532P-hERGmutation
could, in principle, lead to ventricular AP abbreviation [25]. In
addition, the normally slow deactivation of IKr/IhERG means that the
underlying channels are able to conduct current for a period following
completion of AP repolarization, which may normally confer some
protection against premature depolarization [14,34,48]. Consistent
with this, our AP clamp comparison of WT and L532P IhERG (Fig. 5Aii)
shows clearly that WT IhERG had not yet returned fully to baseline
immediately following completion of AP repolarization. By contrast,
the overlain L532P current declines more extensively during this time
(Fig. 5Aii) The marked acceleration of deactivation present for L532P-
hERG might therefore be anticipated to impair the potentially
protective effect of hERG and, if the mutation were to present
clinically, this would likely increase ventricular susceptibility to
premature excitation (although increased susceptibility to the effect
of small magnitude premature depolarizations may be mitigated to
some extent by the slight increase in window IhERG negative to ~
2486 Y.H. Zhang et al. / Biochimica et Biophysica Acta 1808 (2011) 2477–2487−50 mV). As accelerated deactivation is a feature which is shared
with L499P-zERG [25], it could have contributed to the increased
arrhythmia susceptibility of reg mutant zebraﬁsh [25].
The N588K-hERG mutation is well-established to attenuate
markedly the inhibitory actions of Class III but not Class Ia
antiarrhythmic drugs (which depend less than do Class III IKr-selective
drugs on channel inactivation to bind) [10,15,16]. The T618I hERG
mutation has been reported largely to retain sensitivity to inhibition
by high concentrations of quinidine and sotalol, though full
concentration–response data are not available [32]. The Class III
agent dronedarone inhibits WT IhERG in a manner that indicates
contingency on channel gating, with little preference for activated
over inactivated channel states [29]. The compound exhibits reduced
IhERG blocking potency under conditions of substantial inward [K+]
ﬂux, which is suggestive of drug binding in or close to the ion
conduction pathway [29]; docking analysis indicates that the
compound can bind within the channel's inner cavity [40]. Consid-
ering this together with the location of the S4 domain relative to the
inner cavity, it is unlikely that the L532 residue interacts directly with
dronedarone. Rather, it is more likely that altered L532P-hERG
channel gating impairs the ability of the drug to interact with its
binding site. In this regard it is notable that the ~5-fold increase in IC50
for dronedarone seen here is similar to that (~4.2-fold) reported for
structurally-related amiodarone with the N588K hERG mutation [30].
Indeed, the distinct location in the hERG channel of the N588, T618
and L532 residues, together with distinct kinetic effects of the N588K
and L532P mutations under voltage clamp with similarities under AP
clamp, makes the L532P mutant an attractive comparator for future
pharmacological study targeted toward identifying consensus in-
hibitors of different known gain-of-function hERG mutants.
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